Vascular endothelial growth factor B (VEGFB) is a member of the VEGF family, primarily known for its role in regulating lipid metabolism, vascular development, and tissue-specific angiogenesis. Unlike VEGF-A, which strongly promotes blood vessel formation, VEGFB binds selectively to VEGF receptor 1 (VEGFR1) and neuropilin-1 (NRP1), exerting distinct biological effects. It is highly expressed in metabolically active tissues like the heart, skeletal muscle, and brown adipose tissue, where it modulates fatty acid uptake and energy homeostasis.
VEGFB antibodies are essential tools for studying its physiological and pathological functions. Research has linked VEGFB to cardiovascular diseases, diabetes, and cancer, though its mechanisms remain less understood compared to other VEGF members. Antibodies targeting VEGFB enable detection of its expression levels, localization, and interaction with receptors in experimental models. They are widely used in techniques such as Western blotting, immunohistochemistry, and ELISA to explore its role in metabolic regulation or angiogenesis-related disorders.
Therapeutic potential of VEGFB inhibition is under investigation, particularly in obesity and diabetic complications, where its overexpression correlates with abnormal lipid accumulation. However, conflicting studies suggest context-dependent roles, necessitating precise antibody-based profiling. Both monoclonal and polyclonal VEGFB antibodies are available, with specificity validated across species like humans, mice, and rats. Ongoing research aims to clarify VEGFB's dual functions in tissue protection and disease progression, driving demand for reliable antibodies to dissect its complex signaling pathways.